[EN] SUBSTITUTED 4-ARYLOXY AND 4-ARYLSULFANYL-PHENYL-2-AMINOTHIAZOLES AS INHIBITORS OF CELL PROLIFERATION [FR] AMINOTHIAZOLES SUBSTITUES DE 4-ARYLOXY ET DE 4-ARYLSULFANYL-PHENYL-2 EN TANT QU'INHIBITEURS DE LA PROLIFERATION CELLULAIRE
[EN] SUBSTITUTED 4-ARYLOXY AND 4-ARYLSULFANYL-PHENYL-2-AMINOTHIAZOLES AS INHIBITORS OF CELL PROLIFERATION<br/>[FR] AMINOTHIAZOLES SUBSTITUES DE 4-ARYLOXY ET DE 4-ARYLSULFANYL-PHENYL-2 EN TANT QU'INHIBITEURS DE LA PROLIFERATION CELLULAIRE
申请人:UNIV VIRGINIA
公开号:WO2005044263A1
公开(公告)日:2005-05-19
The invention discloses compounds which are substituted 4-aryloxy and 4-arylsulfanyl-phenyl-2-aminothiazoles with anti-cancer activity. The invention futher discloses methods of preparing compounds of the invention. The invention also discloses methods of inhibiting cell proliferation and tumor growth in a subject by administering compounds of the invention to the subject.
Substituted 4-aryloxy and 4-arylsulfanyl-phenyl-2-aminothiazoles as inhibitors of cell proliferation
申请人:Gorczynski J. Michael
公开号:US20070082934A1
公开(公告)日:2007-04-12
The invention discloses compounds which are substituted 4-aryloxy and 4-arylsulfanyl-phenyl-2-aminothiazoles with anti-cancer activity. The invention futher discloses methods of preparing compounds of the invention. The invention also discloses methods of inhibiting cell proliferation and tumor growth in a subject by administering compounds of the invention to the subject.
Synthesis and evaluation of substituted 4-aryloxy- and 4-arylsulfanyl-phenyl-2-aminothiazoles as inhibitors of human breast cancer cell proliferation
作者:Michael J. Gorczynski、Rachel M. Leal、Susan L. Mooberry、John H. Bushweller、Milton L. Brown
DOI:10.1016/j.bmc.2003.12.003
日期:2004.3
Several substituted 4-aryloxy- and 4-arylsulfanyl-phenyl-2-aminothiazoles were synthesized and evaluated for cytotoxic activity against estrogen-positive, estrogen-negative, and adriamycin-resistant human breast cancer cell lines. 4-[4'-(3,4-Dichlorophenoxy)-phenyl]-thiazol-2-yl ammonium iodide demonstrated potent activity against both estrogen-positive and negative breast cancer cell lines with low micromolar (muM) GI(50) values. In addition, we have identified several 2-aminothiazoles that demonstrated selective potency for the adriamycin-resistant and estrogen-negative breast cancer cell lines. The results suggest that these 2-aminothiazoles represent lead compounds for evaluation in animal models of breast cancer. (C) 2003 Elsevier Ltd. All rights reserved.